Skip to content

Search

Optimising influenza vaccine uptake in children with medical comorbidities

Christopher Hannah Blyth Moore MBBS (Hons) DCH FRACP FRCPA PhD OAM BSc (Hons) GradDipClinEpi PhD Centre Head, Wesfarmers Centre of Vaccines and

Targeting interventions to improve influenza control: a proof of principle geomapping study

Christopher Kefyalew Hannah Blyth Alene Moore MBBS (Hons) DCH FRACP FRCPA PhD BSc, MPH, PhD OAM BSc (Hons) GradDipClinEpi PhD Centre Head, Wesfarmers

The PneuCaPTIVE study

Christopher Deborah Blyth Lehmann MBBS (Hons) DCH FRACP FRCPA PhD AO, MBBS, MSc Centre Head, Wesfarmers Centre of Vaccines and Infectious Diseases;

Patient-Reported Outcome Measures for Acute Lower Respiratory Infection (ALRI-PRO): Developing and Establishing Content Validity

Patient (or parent/carer proxy) Reported Outcomes (PROs) are those reported from a patient perspective, capturing how they feel, function, or survive.

PATRIC: Pragmatic Adaptive Trial for Respiratory Infections in Children

Christopher Peter Tom Blyth Richmond Snelling MBBS (Hons) DCH FRACP FRCPA PhD MBBS MRCP(UK) FRACP BMBS DTMH GDipClinEpid PhD FRACP Centre Head,

The pathogen specific burden of hospitalisation for enteric and blood stream infection in children and young people in Western Australia

Hannah Tom Moore Snelling OAM BSc (Hons) GradDipClinEpi PhD BMBS DTMH GDipClinEpid PhD FRACP Head, Infectious Diseases Research Head, Infectious

Understanding the true burden of paediatric respiratory syncytial virus (RSV) in order to optimise prevention programs

Hannah Moore OAM BSc (Hons) GradDipClinEpi PhD Head, Infectious Diseases Research 08 6319 1427 Hannah.moore@thekids.org.au Head, Infectious Diseases

WHO SARI & RSV Surveillance in Australia

Christopher Blyth MBBS (Hons) DCH FRACP FRCPA PhD Centre Head, Wesfarmers Centre of Vaccines and Infectious Diseases; Co-Head, Infectious Diseases

Boosting the influenza vaccine schedule in children with cancer: a prospective open-label study

Current immunization guidelines recommend one dose of influenza vaccine for children aged ≥9 years and two doses for younger or vaccine-naïve children. However, children receiving chemotherapy have an attenuated immune response. We performed a prospective open-label study in children undergoing treatment for cancer at Perth Children's Hospital, Western Australia, to examine the safety and efficacy of a boosted influenza schedule.